IL305506A - Dry powder formulations of dihydroergotamine and their use - Google Patents

Dry powder formulations of dihydroergotamine and their use

Info

Publication number
IL305506A
IL305506A IL305506A IL30550623A IL305506A IL 305506 A IL305506 A IL 305506A IL 305506 A IL305506 A IL 305506A IL 30550623 A IL30550623 A IL 30550623A IL 305506 A IL305506 A IL 305506A
Authority
IL
Israel
Prior art keywords
dry powder
dhe
minutes
weight
amount
Prior art date
Application number
IL305506A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of IL305506A publication Critical patent/IL305506A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL305506A 2021-03-03 2022-03-01 Dry powder formulations of dihydroergotamine and their use IL305506A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156111P 2021-03-03 2021-03-03
PCT/US2022/018306 WO2022187222A1 (en) 2021-03-03 2022-03-01 Dihydroergotamine dry power formulations and methods of use

Publications (1)

Publication Number Publication Date
IL305506A true IL305506A (en) 2023-10-01

Family

ID=80781023

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305506A IL305506A (en) 2021-03-03 2022-03-01 Dry powder formulations of dihydroergotamine and their use

Country Status (11)

Country Link
US (1) US20240033218A1 (https=)
EP (1) EP4301334A1 (https=)
JP (1) JP2024510564A (https=)
KR (1) KR20230152083A (https=)
CN (1) CN117222401A (https=)
AU (2) AU2022228443B2 (https=)
BR (1) BR112023017538A2 (https=)
CA (1) CA3210442A1 (https=)
IL (1) IL305506A (https=)
MX (1) MX2023010120A (https=)
WO (1) WO2022187222A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
WO2008097664A1 (en) * 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
AP3138A (en) * 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
CN103200938B (zh) * 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
AU2013361337A1 (en) * 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
US20140179705A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
AU2014248455B2 (en) * 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
IL265913B2 (en) * 2016-10-14 2024-07-01 Pulmatrix Operating Co Inc Respirable Dry Powder Comprising Itraconazole In Crystalline Form And Its Use For Manufacturing A Medicament For Treating Fungal Infection

Also Published As

Publication number Publication date
EP4301334A1 (en) 2024-01-10
WO2022187222A1 (en) 2022-09-09
AU2025256073A1 (en) 2025-11-13
JP2024510564A (ja) 2024-03-08
CA3210442A1 (en) 2022-09-09
US20240033218A1 (en) 2024-02-01
AU2022228443A1 (en) 2023-09-21
KR20230152083A (ko) 2023-11-02
MX2023010120A (es) 2023-10-30
AU2022228443B2 (en) 2025-07-24
WO2022187222A8 (en) 2023-11-02
CN117222401A (zh) 2023-12-12
BR112023017538A2 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
CN102946868B (zh) 包含抗毒蕈碱药的干粉制剂
CA2550841C (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
AU2020328223B2 (en) Pharmaeutical composition comprising ensifentrine
CN1399540A (zh) 包含福莫特罗的气雾剂组合物
HU230958B1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
AU2020250325A1 (en) Levodopa formulations for rapid relief of parkinson's disease
JP2006514679A (ja) トロスピウム含有組成物
IL305506A (en) Dry powder formulations of dihydroergotamine and their use
JP2024510564A5 (https=)
CA2946165C (en) Rapid relief of motor fluctuations in parkinson's disease
MX2014011576A (es) Composicion farmaceutica.
JP2025526811A (ja) 吸入可能なエピネフリン製剤
JP2000080034A (ja) 風邪用組成物
US20210121577A1 (en) Film coated tablet for the treatment of acute pain
KR20150101993A (ko) 레보도파 혈장 농도의 환자간 변산도의 감소
JP2019108379A (ja) パーキンソン病の運動症状変動の迅速な緩和
KR102259824B1 (ko) 보센탄을 함유한 약학 제제
KR20250099970A (ko) 고온 용융 압출 방식을 이용한 닌테다닙이 함유된 흡입용 건조분말 제형
JP2025506019A (ja) トレプロスチニルイロプロスト併用療法
CA2888979C (en) Reducing inter-patient variability of levodopa plasma concentrations
RU2025105400A (ru) Ингаляционный состав эпинефрина
CN114259481A (zh) 一种奥达特罗复方吸入溶液
WO2023128913A1 (en) A process for the preparation of dry powder compositions for inhalation
WO2005087192A2 (en) Salmeterol inhalation formulations
HK1212258B (en) Levodopa formulations for rapid relief of parkinson's disease